Pfizer reports Phase 3 data for LITFULO in treating nonsegmental vitiligo and plans to submit global regulatory filings.

Pfizer's Litfulo wins Phase 3 for vitiligo; Braveheart Bio eyes $275M IPO testing Hengrui drug; Attovia targets $182M IPO; Pfizer opens London peptide center; Xencor wins $105M…

Pfizer reports Phase 3 data for LITFULO in treating nonsegmental vitiligo and plans to submit global regulatory filings.